Company History
2008
March
HTG receives a Phase I SBIR grant for $300k to develop a microfluidics diagnostic qNPA platform to monitor white blood cell response.
January
TJ Johnson joins HTG as CEO and President.
2007
HTG and the University of Arizona Bio5 Center for Chemical Genomics and Translational Research receive $2M seed funding from Science Foundation Arizona.
December
Jonathan Sheridan joins HTG as VP Commercial Operations.
September
HTG receives a Phase I SBIR grant for $300k to develop a 1600 gene high density qNPA™ array from NIMH.
2006
Bill Radney joins HTG as CEO and President
2005
December
Don Grimm joins HTG’s Board of Directors. Company records its second profitable operating quarter.
September
HTG records its first profitable operating quarter.
July
HTG purchases print and hybridization acceleration IP from Sigma Aldrich.
April
Company completes its “Series B” round of financing.
February
HTG adds two internationally esteemed researchers to its Scientific Advisory Board, contracting the services of Raymond L. Woosley, M.D., Ph.D. and Daniel D. Von Hoff, MD.
Read more
Look for us at the 2008 Merck Technology Symposium, May 13th to 16th in Long Branch, NJ. Find out how the qNPA ArrayPlate will enable your research. Visit us at booth 45.
